Impossible Foods Custom Case Solution & Analysis

Evidence Brief

Financial Metrics

• Total Capital Raised: Over 750 million dollars from investors including Temasek and Horizon Ventures.
• Valuation: Approximately 2 billion dollars during the 2019 funding rounds.
• R and D Investment: Significant portion of capital allocated to molecular biology and protein discovery.
• Price Point: Impossible Burger priced at a premium compared to conventional ground beef, approximately 12 dollars per pound in initial retail trials.
• Market Target: 1.5 trillion dollar global meat market.

Operational Facts

• Primary Production Site: Oakland California facility with a capacity of approximately 500,000 pounds per month.
• Manufacturing Partnership: Agreement with OSI Group to expand production capacity by several multiples.
• Core Technology: Use of soy leghemoglobin produced through genetically engineered yeast fermentation.
• Distribution: Initial entry through high end restaurants followed by 7,000 Burger King locations and subsequent retail launch in Gelsons Markets.
• Regulatory Status: FDA no questions letter received for soy leghemoglobin as a color additive, enabling retail sales of raw product.

Stakeholder Positions

• Pat Brown: Founder and CEO. Position: Animals are an obsolete technology. Goal: Replace animal based food by 2035.
• Investors: Focused on rapid scaling and capturing the flexitarian market segment.
• Incumbent Meat Industry: Increasing pressure to label plant based products as imitation or non meat.
• Consumers: Primary target is meat eaters seeking environmental benefits without sacrificing taste or texture.

Information Gaps

• Unit margins at the Oakland facility versus co-manufacturing sites.
• Specific conversion rates of Burger King trial customers to repeat retail buyers.
• Detailed long term health impact data of concentrated heme consumption.
• Specific cost reduction curve required to reach price parity with commodity beef.

Strategic Analysis

Core Strategic Question

• How can Impossible Foods scale manufacturing and reduce costs to achieve price parity with conventional beef before competitors or incumbent meat processors dominate the plant based category?

Structural Analysis

The industry faces high supplier power regarding specialized ingredients like coconut oil and non-GMO soy. Rivalry is intense as Beyond Meat has already secured a public listing and established a retail lead. The threat of substitutes remains high from both traditional meat and emerging lab-grown alternatives. Impossible Foods relies on its proprietary heme technology as its primary source of differentiation, shifting the competition from a commodity food game to an intellectual property game.

Strategic Options

Option 1: Aggressive Retail and Global Expansion

• Rationale: Capture market share in the grocery segment while the brand has high visibility.
• Trade-offs: Requires massive capital expenditure and risks Diluting brand exclusivity.
• Resources: Extensive co-manufacturing agreements and a global cold-chain logistics network.

Option 2: Product Diversification (Pork and Chicken)

• Rationale: Utilize the heme platform to address larger global markets, specifically pork in Asia.
• Trade-offs: Diverts R and D focus from perfecting the burger and achieving price parity.
• Resources: New production lines and specialized flavor chemistry teams.

Option 3: Technology Licensing Model

• Rationale: License heme technology to existing meat processors to scale without heavy asset investment.
• Trade-offs: Loss of control over end-product quality and brand narrative.
• Resources: Legal and technical integration teams for IP management.

Preliminary Recommendation

Impossible Foods must prioritize Option 1. The window to define the category in the mind of the consumer is narrow. By securing retail shelf space and scaling through partners like OSI Group, the company can drive down the unit cost of heme through volume, making price parity achievable. This path directly supports the 2035 mission by making the product accessible to the mass market, not just premium diners.

Implementation Roadmap

Critical Path

• Month 1-3: Finalize contract manufacturing terms with OSI Group to stabilize supply for nationwide retail rollout.
• Month 3-6: Launch targeted retail expansion in top 10 US metropolitan areas to build data for national grocery chains.
• Month 6-12: Execute international pilot in Singapore and Hong Kong to test regulatory and logistical frameworks for Asian expansion.
• Month 12-18: Implement second generation fermentation process to increase heme yield by 20 percent.

Key Constraints

• Heme Production Bottleneck: The fermentation process for leghemoglobin is the primary limit on total output.
• Cold Chain Infrastructure: Maintaining product integrity from factory to shelf requires specialized logistics that are more expensive than traditional meat distribution.
• Regulatory Approval: International markets have varying standards for genetically modified ingredients, particularly in Europe.

Risk-Adjusted Implementation Strategy

To mitigate execution friction, the company should adopt a phased manufacturing approach. Rather than building internal factories, use the capital to secure long-term capacity with established food processors. This reduces the risk of stranded assets if consumer demand fluctuates. Contingency plans include maintaining a 20 percent buffer in ingredient inventory to protect against supply chain shocks in the non-GMO soy market.

Executive Review and BLUF

Bottom Line Up Front

Impossible Foods must transition from a technology-focused startup to a high-volume consumer goods entity. The primary obstacle to the 2035 goal is not consumer interest but the price gap versus subsidized animal protein. Success requires immediate manufacturing scale through partnerships to reduce costs by 40 percent. Delaying retail dominance to focus on R and D risks ceding the market to Beyond Meat and private label incumbents. The focus must shift from the laboratory to the supply chain.

Dangerous Assumption

The analysis assumes that meat-eating consumers will continue to accept highly processed ingredient lists in exchange for environmental benefits. If health-conscious trends pivot against processed proteins, the current heme-based formula faces a significant demand ceiling regardless of price.

Unaddressed Risks

• Regulatory Protectionism: Traditional meat lobbies may successfully pass legislation in key states or countries that prohibits the use of meat-like terminology, significantly increasing customer acquisition costs.
• Input Volatility: Dependence on specific non-GMO soy and coconut oil sources creates a fragile cost structure that a single climate event could disrupt.

Unconsidered Alternative

The team did not fully explore a B2B ingredient strategy. Instead of selling finished burgers, Impossible could become the primary heme supplier for the entire plant-based industry. This would turn competitors into customers and accelerate the removal of animals from the food system more effectively than a standalone brand could achieve.

Verdict: APPROVED FOR LEADERSHIP REVIEW